Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial
Sponsor: Ottawa Hospital Research Institute
Summary
This will be the first clinical trial to include a strategy designed to enhance the function of autologous progenitor cells by overexpressing eNOS, and the first to use combination gene and cell therapy for the treatment of cardiac disease.
Official title: A Phase IIb, Randomized, Double-blind, Placebo Controlled Study Using Transplantation of Autologous Early Endothelial Progenitor Cells(EPCs) for Patients Who Have Suffered Acute Myocardial Infarction
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
47
Start Date
2013-07-19
Completion Date
2029-11
Last Updated
2025-08-15
Healthy Volunteers
No
Conditions
Interventions
Plasma-Lyte A and 25% Autologous Plasma
Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
Autologous EPCs
Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
Autologous EPCs Transfected with human eNOS
Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
Locations (3)
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
L'institut de cardiologie de Montreal
Montreal, Quebec, Canada